Bone Diseases Clinical Trials

A listing of Bone Diseases medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.

 

Alabama

Birmingham Alabama 35235

A Phase 3 clinical study for patients with Degenerative Disc Disease

Arizona

Scottsdale Arizona 85258

A Phase 3 clinical study for patients with Degenerative Disc Disease

California

Sacramento California 95816

A Phase 3 clinical study for patients with Degenerative Disc Disease

Santa Monica California 90403

A Phase 3 clinical study for patients with Degenerative Disc Disease

Walnut Creek California 94598

A Phase 3 clinical study for patients with Degenerative Disc Disease

Colorado

Greenwood Village Colorado 80111

A Phase 3 clinical study for patients with Degenerative Disc Disease

Florida

Arthritis and Rheumatic Disease Specialities
Aventura Florida 33180

A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis

Center for Arthritis and Rheumatic Diseases
Miami Florida 33173

A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis

Arthritis Center
Palm Harbor Florida 34684

A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis

Sarasota Arthritis Research Center
Sarasota Florida 34239

A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis

Florida Medical Clinic PA
Zephyrhills Florida 33542

A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis

View More ▼

UPDATED

Tamarac Florida 33321

A clinical trial seeking patients for a research study for the treatment of Bone Diseases, Infectious

Georgia

Atlanta Georgia 30329

A Phase 3 clinical study for patients with Degenerative Disc Disease

Illinois

Deerbrook Medical Associates
Vernon Hills Illinois 60061

A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis

View More ▼

Bloomington Illinois 61701

A Phase 3 clinical study for patients with Degenerative Disc Disease

Indiana

Dawes-Fretzin Clinical Research
Indianapolis Indiana 46256

A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis

Kentucky

Graves Gilbert Clinic
Bowling Green Kentucky 42101

A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis

View More ▼

Edgewood Kentucky 41017

A Phase 3 clinical study for patients with Degenerative Disc Disease

Louisiana

Shreveport Louisiana 71103

A Phase 3 clinical study for patients with Degenerative Disc Disease

Minnesota

Rochester Minnesota 55905

A Phase 3 clinical study for patients with Degenerative Disc Disease

Shakopee Minnesota 55379

A Phase 3 clinical study for patients with Degenerative Disc Disease

Missouri

Clayton Medical Research
St. Louis Missouri 63117

A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis

Montana

UPDATED

Butte Montana 59701

A clinical trial seeking patients for a research study for the treatment of Bone Diseases, Infectious

New Jersey

Arthritis and Osteoporosis Associates
Freehold New Jersey 07728

A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis

New York

The Center for Rheumatology
Albany New York 12206

A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis

View More ▼

UPDATED

New York New York 10003

A clinical trial seeking patients for a research study for the treatment of Bone Diseases, Infectious

North Carolina

Charlotte North Carolina 28204

A Phase 3 clinical study for patients with Degenerative Disc Disease

Ohio

Cleveland Ohio 44106

A Phase 3 clinical study for patients with Degenerative Disc Disease

Columbus Ohio 43215

Patients are needed to participate in a clinical research study evaluating NuCel and Deminaralized Bone Matrix for the treatment of Lumbar Degenerative Disc Disease

Columbus Ohio 43214

Patients are needed to participate in a clinical research study evaluating NuCel and Deminaralized Bone Matrix for the treatment of Lumbar Degenerative Disc Disease

Oklahoma

Edmond Oklahoma 73013

A Phase 3 clinical study for patients with Degenerative Disc Disease

Pennsylvania

York Pennsylvania 17402

A Phase 3 clinical study for patients with Degenerative Disc Disease

Rhode Island

Providence Rhode Island 02903

A Phase 3 clinical study for patients with Degenerative Disc Disease

South Carolina

Charleston South Carolina 29406

A Phase 3 clinical study for patients with Degenerative Disc Disease

Texas

Austin Regional Clinic Rheumatology
Austin Texas 78731

A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis

Southwest Rheumatology
Mesquite Texas 75150

A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis

View More ▼

Southlake Texas 76092

A Phase 3 clinical study for patients with Degenerative Disc Disease

Utah

Ogden Utah 84403

A Phase 3 clinical study for patients with Degenerative Disc Disease

Sandy Utah 84070

A Phase 3 clinical study for patients with Degenerative Disc Disease

St. George Utah 84790

A Phase 3 clinical study for patients with Degenerative Disc Disease

Virginia

Richmond Virginia 23235

A Phase 3 clinical study for patients with Degenerative Disc Disease

Washington

The Vancouver Clinic Research Center
Vancouver Washington 98664

A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis

Wenatchee Medical Center
Wenatchee Washington 98801

A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis

Puerto Rico

Centro de Investigacion Clinica
Caguas International 725

A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis

Ponce School Of Medicine
Ponce International 717

A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis

Australia

Clayton Victoria 3168

A Phase 3 clinical study for patients with Degenerative Disc Disease

France

Marseille

Patients are needed to participate in a clinical research study for the treatment of Bone Disease, Fracture Bone or Bone Cyst (CPC Registry)

Marseille 13385

Patients are needed to participate in a clinical research study for the treatment of Bone Disease, Fracture Bone or Bone Cyst (CPC Registry)

Saint-louis

Patients are needed to participate in a clinical research study for the treatment of Bone Disease, Fracture Bone or Bone Cyst (CPC Registry)

Germany

Ratzeburg

Patients are needed to participate in a clinical research study for the treatment of Bone Disease, Fracture Bone or Bone Cyst (CPC Registry)